Argenx: HC Wainwright raises Buy rating, PT to $774 from $720.

Argenx: HC Wainwright raises Buy rating, PT to $774 from $720.

Title: Argenx: HC Wainwright Raises Buy Rating, Target Price to $774

July 02, 2025 — In a significant move for Argenx SE (NASDAQ:ARGX), H.C. Wainwright has upgraded the biotech company's stock to a Buy rating and raised the price target to $774 from $720. This update comes amidst strong progress in Argenx's neuromuscular treatment pipeline and positive second-quarter financial results [1].

Douglas Tsao, an analyst at H.C. Wainwright, cited the company's advancements in the ARGX-119 molecule, which has entered a registrational trial for congenital myasthenic syndromes (CMS). The Phase 1b results demonstrated promising safety and efficacy, boosting investor confidence. ARGX-119 is the third molecule from Argenx to reach late-stage clinical development, further solidifying the company's position in the biotech sector [1].

Additionally, Argenx reported robust second-quarter financials, with Vyvgart revenues reaching $949 million, representing a 20% quarter-over-quarter growth. This performance exceeded both BofA Securities' estimates and consensus expectations. The company's strong global demand growth and the launch of its pre-filled syringe option for at-home dosing contributed to the impressive results [2].

The upgrade reflects the positive outlook on Argenx's pipeline and financial performance. The company's strong balance sheet and profitability metrics also contribute to its appeal among investors. Despite the FDA's evaluation of potential risks associated with Vyvgart Hytrulo, Argenx continues to make strides in its treatment offerings, with the ARGX-119 molecule being a key driver of growth.

References

[1] https://finance.yahoo.com/news/h-c-wainwright-reaffirms-buy-042135381.html
[2] https://za.investing.com/news/analyst-ratings/bofa-securities-raises-argenx-stock-price-target-to-880-on-strong-vyvgart-sales-93CH-3814719